Identification

Name
Clobetasol propionate
Accession Number
DB01013  (APRD00876)
Type
Small Molecule
Groups
Approved
Description

A derivative of prednisolone with high glucocorticoid activity and low mineralocorticoid activity. Absorbed through the skin faster than fluocinonide, it is used topically in treatment of psoriasis but may cause marked adrenocortical suppression.

Structure
Thumb
Synonyms
  • 21-chloro-9-fluoro-11β,17-dihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17-propionate
  • clobetasol 17-propanoate
  • clobetasol 17-propionate
  • Clobetasol propionate E
External IDs
CCI 4725 / CCI-4725 / GR 2/925 / GR-2/925
Active Moieties
NameKindUNIICASInChI Key
ClobetasolprodrugADN79D536H25122-41-2FCSHDIVRCWTZOX-DVTGEIKXSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Clobetasol Cream 0.05%Cream0.05 %TopicalPrempharm Inc1996-12-232005-08-05Canada
Clobetasol Ointment 0.05%Ointment0.05 %TopicalPrempharm Inc1996-12-232005-08-05Canada
Clobetasol PropionateCream0.5 mg/1gTopicalStiefel Laboratories, Inc.2009-12-312010-01-01Us
Clobetasol PropionateOintment0.5 mg/1gTopicalActavis Mid Atlantic LLC,2007-10-12Not applicableUs
Clobetasol PropionateAerosol, foam0.5 mg/1gTopicalPrasco, Laboratories2010-01-152015-11-30Us
Clobetasol PropionateGel0.5 mg/1gTopicalGlades Pharmaceuticals, LLC2009-12-312010-01-01Us
Clobetasol PropionateAerosol, foam0.5 mg/1gTopicalDPT Laboratories, Ltd.2008-03-12Not applicableUs
Clobetasol PropionateCream0.5 mg/1gTopicalStiefel Laboratories, Inc.2009-12-312010-01-01Us
Clobetasol PropionateAerosol, foam0.5 mg/1gTopicalPhysicians Total Care, Inc.2011-08-16Not applicableUs
Clobetasol PropionateOintment0.5 mg/1gTopicalGlades Pharmaceuticals LLC2009-12-312010-01-01Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-clobetasol Propionate Cream 0.05%Cream.05 %TopicalAltimed Pharma Inc.1993-12-312001-09-05Canada
Alti-clobetasol Propionate Ont 0.05%Ointment.05 %TopicalAltimed Pharma Inc.1993-12-312001-09-05Canada
Alti-clobetasol Propionate Scalp Application 0.05%Liquid.05 %TopicalAltimed Pharma Inc.1993-12-312001-09-05Canada
Apo-clobetasol SpraySpray0.05 %TopicalApotex CorporationNot applicableNot applicableCanada
Clobetasol PropionateAerosol, foam0.5 mg/1gTopicalRenaissance Pharma, Inc.2014-02-06Not applicableUs
Clobetasol PropionateCream0.5 mg/1gTopicalTeligent Pharma, Inc.2018-04-17Not applicableUs
Clobetasol PropionateSolution0.4625 mg/1mLTopicalHyGen Pharmaceuticals, Inc.2018-03-23Not applicableUs
Clobetasol PropionateOintment0.5 mg/1gTopicalHi Tech Pharmacal Co., Inc.2010-06-07Not applicableUs
Clobetasol PropionateOintment0.5 mg/1gTopicalLupin Pharmaceuticals2018-06-02Not applicableUs
Clobetasol PropionateOintment0.5 mg/1gTopicalGlenmark Generics, Inc. USA2008-03-032010-08-31Us
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
ClobetaClobetasol propionate (0.5 mg/1g) + Coal tar (23 mg/1mL)KitTiber Laboratories, LLC2011-04-062012-06-30Us
ClobetaClobetasol propionate (0.5 mg/1g) + Coal tar (23 mg/1mL)KitTiber Laboratories, LLC2011-04-062012-06-30Us
International/Other Brands
Clobesol (GlaxoSmithKline) / Dermovate (GlaxoSmithKline) / Embeline (Hi-Tech) / Embeline E (Hi-Tech)
Categories
UNII
779619577M
CAS number
25122-46-7
Weight
Average: 466.97
Monoisotopic: 466.192230046
Chemical Formula
C25H32ClFO5
InChI Key
CBGUOGMQLZIXBE-XGQKBEPLSA-N
InChI
InChI=1S/C25H32ClFO5/c1-5-21(31)32-25(20(30)13-26)14(2)10-18-17-7-6-15-11-16(28)8-9-22(15,3)24(17,27)19(29)12-23(18,25)4/h8-9,11,14,17-19,29H,5-7,10,12-13H2,1-4H3/t14-,17-,18-,19-,22-,23-,24-,25-/m0/s1
IUPAC Name
(1R,2S,10S,11S,13S,14R,15S,17S)-14-(2-chloroacetyl)-1-fluoro-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-14-yl propanoate
SMILES
[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C

Pharmacology

Indication

For short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp.

Associated Conditions
Pharmacodynamics

Like other topical corticosteroids, clobetasol has anti-inflammatory, antipruritic, and vasoconstrictive properties. It is a very high potency topical corticosteroid that should not be used with occlusive dressings. It is recommended that treatment should be limited to 2 consecutive weeks and therapy should be discontinued when adequate results have been achieved.

Mechanism of action

The precise mechanism of the antiinflammatory activity of topical steroids in the treatment of steroid-responsive dermatoses, in general, is uncertain. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Initially, however, clobetasol, like other corticosteroids, bind to the glucocorticoid receptor, which complexes, enteres the cell nucleus and modifies genetic transcription (transrepression/transactivation).

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
Absorption

Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Metabolized, primarily in the liver, and then excreted by the kidneys.

Route of elimination

Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids, including clobetasol propionate and its metabolites, are also excreted into the bile.

Half life
Not Available
Clearance
Not Available
Toxicity

Oral LD50 in rat and mouse is >3000 mg/kg. Topically applied clobetasol can be absorbed in sufficient amounts to produce systemic effects. Symptoms of overdose include thinning of skin and suppression of adrenal cortex (decreased ability to respond to stress).

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be increased when combined with Clobetasol propionate.
(S)-WarfarinThe metabolism of (S)-Warfarin can be increased when combined with Clobetasol propionate.
1-TestosteroneThe risk or severity of edema formation can be increased when 1-Testosterone is combined with Clobetasol propionate.
1,10-PhenanthrolineThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Clobetasol propionate.
16-BromoepiandrosteroneThe risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Clobetasol propionate.
19-norandrostenedioneThe risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Clobetasol propionate.
1alpha-Hydroxyvitamin D5The therapeutic efficacy of 1alpha-Hydroxyvitamin D5 can be decreased when used in combination with Clobetasol propionate.
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Clobetasol propionate.
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Clobetasol propionate.
3,5-diiodothyropropionic acidThe metabolism of 3,5-diiodothyropropionic acid can be increased when combined with Clobetasol propionate.
Food Interactions
Not Available

References

Synthesis Reference

Elks, J., Phillipps, G.H. and May, P.J.; US. Patent 3,721,687; March 20, 1973; assigned to Glaxo Laboratories Limited, England.

General References
Not Available
External Links
KEGG Drug
D01272
PubChem Compound
32798
PubChem Substance
46505670
ChemSpider
30399
BindingDB
39347
ChEBI
31414
ChEMBL
CHEMBL1159650
Therapeutic Targets Database
DAP001183
PharmGKB
PA164744375
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Clobetasol_propionate
AHFS Codes
  • 84:06.00 — Anti-inflammatory Agents
FDA label
Download (95.3 KB)
MSDS
Download (74.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedOtherAtopic Dermatitis (AD)1
1CompletedOtherPsoriasis1
1CompletedTreatmentAtopic Dermatitis (AD)1
1CompletedTreatmentPsoriasis Vulgaris (Plaque Psoriasis)2
1TerminatedOtherPsoriasis1
2Active Not RecruitingTreatmentColon Adenocarcinoma / Rectal Adenocarcinoma / Stage III Colorectal Cancer / Stage III Colorectal Cancer AJCC v7 / Stage IIIA Colorectal Cancer / Stage IIIA Colorectal Cancer AJCC v7 / Stage IIIB Colorectal Cancer / Stage IIIB Colorectal Cancer AJCC v7 / Stage IIIC Colorectal Cancer / Stage IIIC Colorectal Cancer AJCC v7 / Stage IV Colorectal Cancer / Stage IV Colorectal Cancer AJCC v7 / Stage IVA Colorectal Cancer / Stage IVA Colorectal Cancer AJCC v7 / Stage IVB Colorectal Cancer / Stage IVB Colorectal Cancer AJCC v71
2Active Not RecruitingTreatmentOral Lichen Planus1
2CompletedTreatmentPsoriasis1
2CompletedTreatmentVulvar Lichen Sclerosus1
2RecruitingTreatmentOral Lichen Planus2
2TerminatedTreatmentVulvar Lichen Sclerosus1
3CompletedTreatmentAlopecia Areata (AA)1
3CompletedTreatmentChronic Stable Plaque Psoriasis1
3CompletedTreatmentPsoriasis2
3CompletedTreatmentScalp Psoriasis1
4CompletedNot AvailablePsoriasis1
4CompletedTreatmentAlopecia Areata (AA)1
4CompletedTreatmentChronic Stable Plaque Psoriasis1
4CompletedTreatmentDermatitis, Chronic1
4CompletedTreatmentHand Dermatosis1
4CompletedTreatmentHypertrophic Scars1
4CompletedTreatmentPsoriasis3
4CompletedTreatmentPsoriasis Vulgaris (Plaque Psoriasis)5
4CompletedTreatmentPsoriatic Nails1
4CompletedTreatmentScalp Psoriasis1
4RecruitingPreventionBullous Pemphigoid (BP)1
4Unknown StatusTreatmentDermatitis, Contact / Dermatitis, Occupational1
4Unknown StatusTreatmentHair Thinning1
Not AvailableCompletedTreatmentVulvar Lichen Sclerosus1
Not AvailableTerminatedNot AvailablePsoriasis1

Pharmacoeconomics

Manufacturers
  • Perrigo israel pharmaceuticals ltd
  • Connetics corp
  • Stiefel laboratories inc
  • Actavis mid atlantic llc
  • E fougera div altana inc
  • Taro pharmaceuticals inc
  • Teva pharmaceuticals usa
  • Altana inc
  • Stiefel a gsk co
  • Taro pharmaceuticals usa inc
  • Hi tech pharmacal co inc
  • Perrigo co
  • Galderma laboratories l p
  • Nycomed us inc
  • Galderma laboratories inc
  • Tolmar inc
  • Wockhardt eu operations (swiss) ag
  • Galderma laboratories lp
Packagers
  • Accra Pac Inc.
  • Ameri-Pac Inc.
  • A-S Medication Solutions LLC
  • Contract Pharm
  • Dermalogix
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • DPT Laboratories Ltd.
  • E. Fougera and Co.
  • Galderma Laboratories
  • GlaxoSmithKline Inc.
  • Glenmark Generics Ltd.
  • Hi Tech Pharmacal Co. Inc.
  • Inyx Usa Ltd.
  • Nycomed Inc.
  • Palmetto Pharmaceuticals Inc.
  • Perrigo Co.
  • Pharma Pac LLC
  • Pharmaderm
  • Pharmedix
  • Physicians Total Care Inc.
  • Prasco Labs
  • Preferred Pharmaceuticals Inc.
  • Quality Care
  • Rebel Distributors Corp.
  • Stat Rx Usa
  • Stiefel Labs
  • Taro Pharmaceuticals USA
  • Teva Pharmaceutical Industries Ltd.
  • Watson Pharmaceuticals
  • Wockhardt Ltd.
Dosage forms
FormRouteStrength
LiquidTopical.05 %
Kit
Aerosol, foamTopical0.5 mg/1g
CreamTopical.5 mg/1g
CreamTopical0.5 mg/1g
EmulsionTopical0.5 mg/1g
GelTopical.05 mg/1g
GelTopical0.05 mg/1g
GelTopical0.5 mg/1g
LotionTopical.05 mg/100mL
LotionTopical0.05 g/100mL
LotionTopical0.5 mg/1mL
OintmentTopical.5 mg/1g
OintmentTopical0.5 mg/1g
ShampooTopical.5 mg/1mL
ShampooTopical0.05 g/100mL
SolutionTopical0.462 mg/1mL
SolutionTopical0.5 mg/1mL
LotionTopical.05 g/100mL
LotionTopical0.05 mL/100mL
SprayTopical0.05 g/1mL
SprayTopical0.5 mg/1mL
ShampooTopical0.05 %
ShampooTopical0.05 mL/100mL
SprayTopical0.05 %
ShampooTopical0.5 mg/1mL
Kit0.5 mg/1mL
SolutionTopical0.4625 mg/1mL
SolutionTopical0.5 mg/1g
SolutionTopical.05 %
CreamTopical0.25 mg/1g
CreamTopical0.05 %
OintmentTopical0.05 %
LotionTopical0.05 %
CreamTopical.05 %
OintmentTopical.05 %
Aerosol, foamTopical0.05 %
SolutionTopical0.05 %
Prices
Unit descriptionCostUnit
Clobex 0.05% Lotion 118ml Bottle513.56USD bottle
Clobex Spray 0.05% Liquid 125ml Bottle501.7USD bottle
Olux 0.05% Foam 100 gm Can443.77USD can
Olux-E 0.05% Foam 100 gm Can384.32USD can
Olux Olux-E Complete Pack 0.05 & 0.05% Miscellaneous 110 gm Can373.65USD can
Clobex 0.05% Shampoo 118ml Bottle365.67USD bottle
Clobetasol Propionate 0.05% Foam 100 gm Can326.37USD can
Clobex 0.05% Lotion 59ml Bottle280.8USD bottle
Clobex Spray 0.05% Liquid 59ml Bottle278.93USD bottle
Olux 0.05% Foam 50 gm Can239.07USD can
Temovate 0.05% Cream 60 gm Tube234.19USD tube
Temovate 0.05% Gel 60 gm Tube234.19USD tube
Temovate E 0.05% Cream 60 gm Tube234.19USD tube
Clobetasol Propionate 0.05% Foam 50 gm Can177.05USD can
Temovate 0.05% Ointment 30 gm Tube132.55USD tube
Temovate 0.05% Solution 50ml Bottle113.82USD bottle
Temovate 0.05% Cream 45 gm Tube95.43USD tube
Clobetasol Propionate 0.05% Gel 60 gm Tube93.82USD tube
Temovate 0.05% Ointment 15 gm Tube82.1USD tube
Clobetasol 17-prop powder70.74USD g
Clobetasol Propionate 0.05% Cream 60 gm Tube64.15USD tube
Clobetasol Propionate 0.05% Ointment 60 gm Tube64.15USD tube
Clobetasol Propionate 0.05% Gel 30 gm Tube51.66USD tube
Clobetasol Propionate 0.05% Ointment 45 gm Tube50.56USD tube
Clobetasol Propionate 0.05% Cream 45 gm Tube48.57USD tube
Temovate 0.05% Gel 15 gm Tube47.38USD tube
Temovate E 0.05% Cream 15 gm Tube44.9USD tube
Clobetasol Propionate 0.05% Solution 50ml Bottle41.18USD bottle
Clobetasol Propionate 0.05% Cream 30 gm Tube34.79USD tube
Clobetasol Propionate 0.05% Ointment 30 gm Tube34.79USD tube
Clobetasol Propionate 0.05% Gel 15 gm Tube28.86USD tube
Clobetasol Propionate 0.05% Solution 25ml Bottle26.99USD bottle
Clobetasol Propionate 0.05% Cream 15 gm Tube24.94USD tube
Clobetasol Propionate 0.05% Ointment 15 gm Tube24.1USD tube
Olux 0.05% foam6.77USD g
Olux-e 0.05% foam5.9USD g
Clobex 0.05% topical lotion4.58USD ml
Temovate emollient 0.05% crm3.75USD g
Olux-olux-e complete pack3.43USD g
Temovate 0.05% cream3.29USD g
Cormax 0.05% cream2.06USD g
Embeline 0.05% cream1.86USD g
Clobetasol 0.05% cream1.43USD g
Dermovate 0.05 % Cream0.72USD g
Dermovate 0.05 % Ointment0.72USD g
Dermovate 0.05 % Lotion0.63USD g
Mylan-Clobetasol 0.05 % Cream0.38USD g
Mylan-Clobetasol 0.05 % Ointment0.38USD g
Novo-Clobetasol 0.05 % Cream0.38USD g
Novo-Clobetasol 0.05 % Ointment0.38USD g
Pms-Clobetasol 0.05 % Cream0.38USD g
Pms-Clobetasol 0.05 % Ointment0.38USD g
Ratio-Clobetasol 0.05 % Cream0.38USD g
Ratio-Clobetasol 0.05 % Ointment0.38USD g
Taro-Clobetasol 0.05 % Cream0.38USD g
Taro-Clobetasol 0.05 % Ointment0.38USD g
Mylan-Clobetasol 0.05 % Lotion0.33USD g
Pms-Clobetasol 0.05 % Lotion0.33USD g
Ratio-Clobetasol 0.05 % Lotion0.33USD g
Taro-Clobetasol 0.05 % Lotion0.33USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2333869No2009-01-062019-09-08Canada
CA2333427No2007-01-092019-06-17Canada
US6126920No1996-03-012016-03-01Us
US8460641No2008-11-052028-11-05Us
US8962000No2005-08-312025-08-31Us
US6730288No1999-09-082019-09-08Us
US7029659No1999-09-082019-09-08Us
US6106848No1997-09-222017-09-22Us
US7700081No2002-01-032022-01-03Us
US8066975No1999-06-172019-06-17Us
US7316810No1999-06-172019-06-17Us
US8066976No1999-06-172019-06-17Us
US5990100No1998-03-242018-03-24Us
US5972920No1998-02-122018-02-12Us
US9855334No2015-03-112035-03-11Us
US9956231No2010-08-312030-08-31Us
US10064875No2010-08-312030-08-31Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)226Elks, J., Phillipps, G.H. and May, P.J.; US. Patent 3,721,687; March 20, 1973; assigned to Glaxo Laboratories Limited, England.
water solubility3.86 mg/LNot Available
logP3.50SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.00413 mg/mLALOGPS
logP3.49ALOGPS
logP4.18ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)13.63ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area80.67 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity119.32 m3·mol-1ChemAxon
Polarizability48.28 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9814
Caco-2 permeable+0.812
P-glycoprotein substrateSubstrate0.7852
P-glycoprotein inhibitor INon-inhibitor0.7375
P-glycoprotein inhibitor IINon-inhibitor0.7683
Renal organic cation transporterNon-inhibitor0.7883
CYP450 2C9 substrateNon-substrate0.8533
CYP450 2D6 substrateNon-substrate0.9077
CYP450 3A4 substrateSubstrate0.7967
CYP450 1A2 substrateNon-inhibitor0.9412
CYP450 2C9 inhibitorNon-inhibitor0.8713
CYP450 2D6 inhibitorNon-inhibitor0.8327
CYP450 2C19 inhibitorNon-inhibitor0.9126
CYP450 3A4 inhibitorNon-inhibitor0.5411
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9129
Ames testNon AMES toxic0.8848
CarcinogenicityNon-carcinogens0.935
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.1435 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9314
hERG inhibition (predictor II)Non-inhibitor0.5569
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a6r-0596000000-b19d97ac39952d18b68e
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03mj-3971000000-8f42562c23aaf5e5d240

Taxonomy

Description
This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Pregnane steroids
Direct Parent
Gluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
Steroid esters / 20-oxosteroids / 11-beta-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Alpha-acyloxy ketones / Alpha-chloroketones / Fluorohydrins / Cyclic ketones
show 10 more
Substituents
Progestogin-skeleton / Steroid ester / 20-oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 11-hydroxysteroid / 11-beta-hydroxysteroid / Oxosteroid / 9-halo-steroid / Halo-steroid
show 27 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
11beta-hydroxy steroid, glucocorticoid, 20-oxo steroid, fluorinated steroid, 3-oxo-Delta(1),Delta(4)-steroid, chlorinated steroid (CHEBI:31414)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Fitzgerald P, O'Brien SM, Scully P, Rijkers K, Scott LV, Dinan TG: Cutaneous glucocorticoid receptor sensitivity and pro-inflammatory cytokine levels in antidepressant-resistant depression. Psychol Med. 2006 Jan;36(1):37-43. Epub 2005 Oct 28. [PubMed:16255837]
  2. Hofmann TG, Hehner SP, Bacher S, Droge W, Schmitz ML: Various glucocorticoids differ in their ability to induce gene expression, apoptosis and to repress NF-kappaB-dependent transcription. FEBS Lett. 1998 Dec 28;441(3):441-6. [PubMed:9891987]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Ahmad N, Mukhtar H: Cytochrome p450: a target for drug development for skin diseases. J Invest Dermatol. 2004 Sep;123(3):417-25. doi: 10.1111/j.0022-202X.2004.23307.x. [PubMed:15304077]
  2. Olux monograph [File]

Drug created on June 13, 2005 07:24 / Updated on October 15, 2018 04:36